Pathophysiology of high remnant lipoproteinemia underlying atherosclerotic disease in Japan and development of a new assay for remnant lipoproteins
Pathophysiology of high remnant lipoproteinemia underlying atherosclerotic disease in Japan and development of a new assay for remnant lipoproteins
批准号:
16590455
负责人:
YAMAMURA Taku
金额:
$2.24万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2004
资助国家:
日本
项目状态:
已结题
起止时间:
2004 至 2006
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Recent studies have demonstrated that impaired clearance of chylomicron remnant causes postprandial hyper-lipidemia (PPHL), which suggested as one of the risk factors for coronary heart disease (CHD). Furthermore, the increase in very low density lipoprotein (VLDL) remnant in metabolic syndrome (visceral fat syndrome) is an important therapeutic target for the prevention of CHD in developed countries. The measurement of serum remnant concentrations, however, remains complicated and there are as yet no systems which can work on automated analyzers. In this study, we developed a new assay for serum remnant cholesterol using specific detergents and investigated its significance for PPHL.Remnant lipoproteins in serum were selectively homogenized by specific detergents and phospholipase D followed by enzymatic determination of cholesterol content as remnant lipoprotein-cholesterol (RemL-C). Healthy controls (n=39), type IIa (Ha HL, n=3), and type IIb HL, n=6) hyperlipoproteinemic patients w … More ere investigated. Type IIa and IIb HL were subjected to an oral fat loading test (30 g fat/m^2) before and after atorvastatin treatment (10 mg/day) for 4 weeks. Furthermore, we used gel filtration to analyze hypertriglyceridemic serum. The apolipoprotein (apo) B-48 concentrations were assessed with the chemiluminescence method using a monoclonal antibody to apoB-48 established by us.In healthy controls, the mean fasting value (MEAN) and standard deviation (SD) of RemL-C were 3.4 and 1.4 mg/dL, respectively. RemL-C of lib HL was higher than the normal range (MEAN + 2SD). Oral fat loading test results showed that in both IIa and lib HL, the RemL-C peaked 1 or 2 hrs behind the TG peak. Atorvastatin treatment reduced the area under the curve of TG and RemL-C drastically especially in IIb HL. In the gel filtra-tion analysis, the peak of RemL-C was observed at the position of so-called large VLDL and coincided with the peak of apoB-48. These findings demonstrate that our assay provides a simple protocol for general use for remnant cholesterol measurement. Atorvastatin was found to improves PPHL, at least partly through a mechanism associated with exogenous lipoprotein metabolism. Less
期刊论文(32)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
高脂血症・肥満と精査
高脂血症/肥胖及详细检查
DOI:
--
发表时间:
2005
期刊:
臨床と研究 82・8
影响因子:
--
作者:
[Chika Miyagi, Nobuhisa Yamane, Bhusal Yogesh, 石神雅人]
通讯作者:
石神雅人
レムナントリポ蛋白の代謝と臨床的意義
残余脂蛋白的代谢及临床意义
DOI:
--
发表时间:
2006
期刊:
Progress Medicine 26・10
影响因子:
--
作者:
[Y.Bhusal, C.M.Shiohira, N.Yamane, Takano T, 山村 卓]
通讯作者:
山村 卓
III 型高脂血症の診断はどうすればいいのですか?「トリグリセライドと動脈硬化-メタボリックシンドロームの観点から」(寺本民生、編)
我应该如何诊断 III 型高脂血症?“甘油三酯和动脉硬化 - 从代谢综合征的角度”(寺本田雄主编)
DOI:
--
发表时间:
2006
期刊:
影响因子:
--
作者:
[山村 卓, 石神眞人]
通讯作者:
石神眞人
脂質代謝異常を探る新たなツールとしての臨床検査 低脂血症の病因、診断
临床检测作为检测脂质代谢异常的新工具:低脂血症的发病机制和诊断
DOI:
--
发表时间:
2006
期刊:
臨床化学 85・3
影响因子:
--
作者:
[石神雅人, 山下静也, 山村 卓]
通讯作者:
山村 卓
糖尿病と遺伝子(分担執筆)
糖尿病和基因(合著者)
DOI:
--
发表时间:
2005
期刊:
影响因子:
--
作者:
[山村 卓, 石神眞人, 石神眞人]
通讯作者:
石神眞人
共 13 条
Medical examinations for obesity and hyperlipidemia with a focus on pediatric metabolic syndrome, and abnormalities of plasma lipoprotein
-
批准号:22590525
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.91万
-
财政年份:2010
-
负责人:YAMAMURA Taku
-
依托单位:
Remnant Lipoprotein Metabolism in Metabolic Syndrome, and the State of Obesity and Hyperlipidemia in Schoolchildren
-
批准号:19590558
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.91万
-
财政年份:2007
-
负责人:YAMAMURA Taku
-
依托单位:
Studies on the regulation of cholesteryl ester synthesis and mechanism of lipid accumulation in macrophage cells
-
批准号:07457228
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$4.67万
-
财政年份:1995
-
负责人:YAMAMURA Taku
-
依托单位:
Studies on Hyperlipoproteinemic Trait, Especially Plasma Apolipoprotein Mutants, as a Risk Factor for Atherosclerosis
-
批准号:05454325
-
项目类别:Grant-in-Aid for General Scientific Research (B)
-
资助金额:$4.35万
-
财政年份:1993
-
负责人:YAMAMURA Taku
-
依托单位:
Plasma Apolipoprotein Mutants and their Implication on Lipoprotein Metabolism
-
批准号:02671116
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.47万
-
财政年份:1990
-
负责人:YAMAMURA Taku
-
依托单位:
海外基金